# data[].attributes.body
1 publication

# data[].attributes.body
1 publication

# data[].attributes.headline
Pancreatic Cancer in People With HIV: A Case–Control Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. April 1. (2025)

# data[].attributes.subject
Pancreatic Cancer in People With HIV: A Case–Control Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. April 1. (2025)

# data[].attributes.body
Chawki, S., Hamet, G., Brun, A., Lourenco, N., Bouchaud, O., Bottero, J., Sellier, P., Molina, J.-M.

# data[].attributes.headline
Prescriptions of generic antiretroviral drugs in three healthcare centers in the Paris area, France. AIDS (2024).

# data[].attributes.subject
Prescriptions of generic antiretroviral drugs in three healthcare centers in the Paris area, France. AIDS (2024).

# data[].attributes.body
Leroy, P., Diamantis, S., Sellier, P.-O., Hamet, G.,

Brun, A., Rozenbaum, W., Molina, J.-M.

# data[].attributes.body
3 publications scientifiques

# data[].attributes.headline
Incidence and Management of Complex Kidney Situations Among On-demand and Daily. JAIDS (2023).

# data[].attributes.subject
Incidence and Management of Complex Kidney Situations Among On-demand and Daily. JAIDS (2023).

# data[].attributes.body
LIEGEON, G., BRUN, A., HAMET, G., ZEGGAGH, J.,
PINTADO, C., LOZE, B., PONSCARME, D., ROZENBAUM, W., MOLINA, J.-M.

# data[].attributes.headline
Updated mortality and causes of death in 2020-2021 in people living with HIV: a multicenter study in France. AIDS (2023).

# data[].attributes.subject
Updated mortality and causes of death in 2020-2021 in people living with HIV: a multicenter study in France. AIDS (2023).

# data[].attributes.body
SELLIER, P., ALEXANDRE-CASTOR, G., BRUN, A., HAMET, G., BOUCHAUD, O., LEROY, P., DIAMANTIS, S., CHABROL, A., MACHADO, M., BOULDOUYRE, M.-A., DE CASTRO, N., ROZENBAUM, W., MOLINA, J.-M. for the « Commission Recherche Clinique du COREVIH Ile-de-France Est ».

# data[].attributes.headline
Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV : a multicenter cohort study. AIDS Research and Therapy. 20:1 (2023)

# data[].attributes.subject
Safety and efficacy of switching to elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate in treatment-experienced people with HIV : a multicenter cohort study. AIDS Research and Therapy. 20:1 (2023)

# data[].attributes.body
De Castro, N., Brun, A., Sellier, P., Hamet, G., Méchaï, F., Garrait, V., Chabrol, A., Bouldouye, M.-A., Froguel, E., Troisvallets, D., Caraux-Paz, P., Delaugerre, C., Rozenbaum, W., Molina, J.-M.

# data[].attributes.body
1 publication scientifique
3 posters

# data[].attributes.body
1 publication scientifique
3 posters

# data[].attributes.body
1 poster

# data[].attributes.body
4 posters
1 publication scientifique

# data[].attributes.body
2 posters

# data[].attributes.body
1 poster

# data[].attributes.body
4 posters

# data[].attributes.body
1 présentation orale

# data[].attributes.body
1 publication scientifique

# data[].attributes.body
1 publication scientifique

# data[].attributes.body
2 posters

# data[].attributes.body
6 posters
1 présentation orale
1 publication scientifique

# data[].attributes.headline
Expositions accidentelles à risque viral professionnelles et sexuelles : Données des rapports d’activité 2011 des COREVIH. Vers une amélioration du recueil par une simplification et une standardisation ? SFLS. (2013).

# data[].attributes.subject
Expositions accidentelles à risque viral professionnelles et sexuelles : Données des rapports d’activité 2011 des COREVIH. Vers une amélioration du recueil par une simplification et une standardisation ? SFLS. (2013).

# data[].attributes.body
Rouveix, E., Bouvet, E., Vernat, F., Chansombat, M., Hamet, G., Pellissier, G.

# data[].attributes.headline
Comparaison des hospitalisations de courte et longue durée des patients infectés par le VIH sur le territoire de la COREVIH Ile-de-France Nord en 2013. SFLS. (2014).

# data[].attributes.subject
Comparaison des hospitalisations de courte et longue durée des patients infectés par le VIH sur le territoire de la COREVIH Ile-de-France Nord en 2013. SFLS. (2014).

# data[].attributes.body
Hamet, G., Godard, C., Deschaud, Le Gac, S., Lepretre, A., Rioux, C., Joly, V., El Hajj, E., Blum, L., Yazdanpanah, Y., Bouvet, E. C

# data[].attributes.headline
Evaluation de la prise en charge (PEC) des Expositions Accidentelles à risque de transmission virale (EAV) en 2012 dans un Centre Hospitalier Universitaire (CHU). SFLS. (2014).

# data[].attributes.subject
Evaluation de la prise en charge (PEC) des Expositions Accidentelles à risque de transmission virale (EAV) en 2012 dans un Centre Hospitalier Universitaire (CHU). SFLS. (2014).

# data[].attributes.body
Chansombat, M., Hamet, G., Tosini, W., Abiteboul, D., Rumi, S., Casalino, E., Bouvet, E.

# data[].attributes.headline
Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. Journal of Antimicrobial Chemotherapy Advance. 67(9): 2231-2235. (2012).

# data[].attributes.subject
Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome. Journal of Antimicrobial Chemotherapy Advance. 67(9): 2231-2235. (2012).

# data[].attributes.body
Charpentier, C., Landman, R., Laouénan, C., Joly, V., Hamet, G., Damond, F., Brun-Vézinet, F., Mentré, F., Descamps, D., Yeni, P.

# data[].attributes.headline
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. Liver International. 32(1) : 93-101. (2011).

# data[].attributes.subject
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G. Liver International. 32(1) : 93-101. (2011).

# data[].attributes.body
Lada, O., Gervais, A., Branger, M., Peytavin, G., Roquebert, B., Collin, G., Fraqueiro, G., Moucari, R., Hamet, G., Martinot-Peignoux, M., Matheron, S., Marcellin, P.

# data[].attributes.attachment_link.title
Article_2012_Liver International 20012 - liv2601

# data[].attributes.headline
Management of accidental exposure to HIV : The COREVIH 2011 activity report. Médecine et Maladies Infectieuses. 44(3) : 112-116. (2014 March 6).

# data[].attributes.subject
Management of accidental exposure to HIV : The COREVIH 2011 activity report. Médecine et Maladies Infectieuses. 44(3) : 112-116. (2014 March 6).

# data[].attributes.body
Rouveix, E., Bouvet, E., Vernat, F., Chansombat, M., Hamet, G., Pellissier, G.

# data[].attributes.headline
Comparaison des files actives 2011 et 2013 des nouveaux patients dépistés VIH pris en charge dans la COREVIH Ile-de-France Nord. SFLS. (2014).

# data[].attributes.subject
Comparaison des files actives 2011 et 2013 des nouveaux patients dépistés VIH pris en charge dans la COREVIH Ile-de-France Nord. SFLS. (2014).

# data[].attributes.body
Hamet, G., Deschaud, M., Chansombat, M., Le Gac, S., El Hajj, E., Lepretre, A., Yeni, P., Yazdanpanah, Y., Blum, L., Bouvet, E.

# data[].attributes.headline
Impact de l'absence de titre de séjour sur la prise en charge de l'infection VIH dans la COREVIH Ile-de-France Nord. SFLS. (2015).

# data[].attributes.subject
Impact de l'absence de titre de séjour sur la prise en charge de l'infection VIH dans la COREVIH Ile-de-France Nord. SFLS. (2015).

# data[].attributes.body
Deschaud, M., Khuong, M.A., Hamet, G., Baurienne, S., Rochon, J., Leprêtre, A., Bouvet, E., Yazdanpanah, Y., Blum, L.

# data[].attributes.headline
Does Ethnic Origin Influence Timing, Choice and Response to First Line Antiretroviral Therapy in France? HIV Drug Therapy Glasgow. (2016).

# data[].attributes.subject
Does Ethnic Origin Influence Timing, Choice and Response to First Line Antiretroviral Therapy in France? HIV Drug Therapy Glasgow. (2016).

# data[].attributes.body
Gatey, C., Brun, A., Turpault, I., Sellier, P., Bouchaud, O., Patey, O., Garrait, V., Jeantils, V., Chabrol, A., Diamantis, S., Grégoire-Faucher, V., Froguel, E., Son, O., Lamy, S., Routier, C., Ait Mohand, H., Turner, L., Hamet, G., Delaugerre, C., Rozenbaum, W., Molina, J.M. and the COREVIH Ile-de-France Est.

# data[].attributes.headline
Safety and efficacy of switching to E/C/F/T (Stribild®) in treatment experienced HIV-1 infected patients: A multicenter cohort study. EACS. (2017).

# data[].attributes.subject
Safety and efficacy of switching to E/C/F/T (Stribild®) in treatment experienced HIV-1 infected patients: A multicenter cohort study. EACS. (2017).

# data[].attributes.body
De Castro, N., Brun, A., Sellier, P., Hamet, G., Mechai, F., Garrait, V., Chabrol, A., Bouldouyre, M.A., Froguel, E., Troisvallets, D., Patey, O., Molina, J.M.

# data[].attributes.headline
Synthèse épidémiologique des hépatites B et C dans la population de patients infectés par le VIH en Ile de France en 2016. AFRAVIH. (2018)

# data[].attributes.subject
Synthèse épidémiologique des hépatites B et C dans la population de patients infectés par le VIH en Ile de France en 2016. AFRAVIH. (2018)

# data[].attributes.body
Valantin, M.-A., Gerbe, J., Agher, R., Papot, E., Blanc, C., Brun, A., Hamet, G., Pietri, M.-P., Cros, A., Mackoumbou, C., Deschaud, M., Marcou, M., Hamidi M., Fonquernie L., Louasse, P., Bouvet, E., Rouveix, E., Rozenbaum, W., Sobel, A., Katlama, C.

# data[].attributes.headline
Does region of origin influence timing of and outcome on first line antiretroviral therapy in France? HIV medicine. 20(2): 175-181. (2019).

# data[].attributes.subject
Does region of origin influence timing of and outcome on first line antiretroviral therapy in France? HIV medicine. 20(2): 175-181. (2019).

# data[].attributes.body
Gatey, C., Brun, A., Hamet, G., Diamantis, S., Sellier, P., Bouchaud, O., Garrait, V., Rozenbaum, W., Molina, J-.M., Abgrall, S., COREVIH Ile de France Est Research Group.

# data[].attributes.headline
Mortality of people living with HIV in Paris Area from 2011 to 2015. AIDS research and human retroviruses. AIDS research and human retroviruses. 36(5):373-380. (2020).

# data[].attributes.subject
Mortality of people living with HIV in Paris Area from 2011 to 2015. AIDS research and human retroviruses. AIDS research and human retroviruses. 36(5):373-380. (2020).

# data[].attributes.body
Sellier, P., Hamet, G., Brun, A., Ponscarme, D., De Castro, N., Alexandre, G., Rozenbaum, W., Molina, J.-M., Abgrall, S.

# data[].attributes.headline
Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV/TB co-infection. A multicenter cohort study in France. EACS (2021)

# data[].attributes.subject
Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV/TB co-infection. A multicenter cohort study in France. EACS (2021)

# data[].attributes.body
Kherabi, Y., De Castro, N., Sellier, P., Hamet, G., Brun, A., Mechai, F., Joly, V., Yazdanpanah, Y., Molina, J.-M.

# data[].attributes.headline
Causes de décès chez les patients infectés par le VIH au cours de la pandémie Covid-19 : Une étude prospective multicentrique dans la région parisienne. SFLS (2022)

# data[].attributes.subject
Causes de décès chez les patients infectés par le VIH au cours de la pandémie Covid-19 : Une étude prospective multicentrique dans la région parisienne. SFLS (2022)

# data[].attributes.body
Sellier, P., Alexandre-Castor, G., Bouchaud, O., Diamantis, S., Hamet, G., Brun, A., Chabrol, A., Machado, M., Bouldouyre, M-A., Ponscarme, D., De Castro, N., Leroy, P., Turpault, I., Rozenbaum, W., Molina, J.-M.

# data[].attributes.headline
Use of generic antiretroviral drugs in 2021 in three health centres in the Paris area, France. HIV Drug Therapy Glasgow (2022)

# data[].attributes.subject
Use of generic antiretroviral drugs in 2021 in three health centres in the Paris area, France. HIV Drug Therapy Glasgow (2022)

# data[].attributes.body
Leroy, P., Diamantis, S., Sellier, P., Hamet, G., Brun, A., Rozenbaum, W., Molina, J.-M.

# data[].attributes.headline
Pancreatic cancer in people with HIV: an emerging concern? HIV Drug Therapy Glasgow (2022)

# data[].attributes.subject
Pancreatic cancer in people with HIV: an emerging concern? HIV Drug Therapy Glasgow (2022)

# data[].attributes.body
Chawki, S., Lourenco, N., Hamet, G., Brun, A., Bouchaud, O., Bottero, J. , Sellier, P., Molina, J.-M.

# data[].attributes.headline
Silent coronary heart disease in patients on ART: Prevalence and risk factors. AIDS (2022).

# data[].attributes.subject
Silent coronary heart disease in patients on ART: Prevalence and risk factors. AIDS (2022).

# data[].attributes.body
Cresta, M., Brun, A., Merlet, P., Hamet, G., Sideris, G., De Castro, N., Rozenbaum, W., Lascoux-Combe, C., Molina, J.-M.

Lien sur l'Abstract : https://programme.aids2022.org/Abstract/Abstract/?abstractid=5736

https://aids2022.org/wp-content/uploads/2022/08/AIDS2022_abstract_book.pdf

# data[].attributes.headline
Prescriptions de génériques d’ARV dans 3 centres du COREVIH IDF-EST. JNI (2022) 

# data[].attributes.subject
Prescriptions de génériques d’ARV dans 3 centres du COREVIH IDF-EST. JNI (2022) 

# data[].attributes.body
Leroy, P., Diamantis, S., Sellier, P., Hamet, G., Brun, A., Rozenbaum, W., Molina, J.-M.

# data[].attributes.headline
Cardiopathie ischémique silencieuse chez les patients sous ARV : Prévalence et Facteurs de risque. JNI (2022).

# data[].attributes.subject
Cardiopathie ischémique silencieuse chez les patients sous ARV : Prévalence et Facteurs de risque. JNI (2022).

# data[].attributes.body
Cresta, M., Brun, A., Merlet, P., Hamet, G., Sideris, G., De Castro, N., Rozenbaum, W., Lascoux-Combe, C., Molina, J.-M.

# data[].attributes.headline
Incidence et facteurs associés aux effets indésirables rénaux graves chez les usagers de PrEP. JNI (2022).

# data[].attributes.subject
Incidence et facteurs associés aux effets indésirables rénaux graves chez les usagers de PrEP. JNI (2022).

# data[].attributes.body
Liegeon, G., Brun, A., Hamet, G., Zeggagh, J., Pintado, C., Loze, B., Tateo, M., Ponscarme, D., Rozenbaum, W., Molina, J.-M.

# data[].attributes.headline
Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV/TB co-infection. A multicenter cohort study in France. JAIDS (2022)

# data[].attributes.subject
Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV/TB co-infection. A multicenter cohort study in France. JAIDS (2022)

# data[].attributes.body
Kherabi, Y., De Castro, N., Sellier, P., Hamet, G., Brun, A., Mechai, F., Joly, V., Yazdanpanah, Y., Molina, J.-M.

# data[].attributes.attachment_link.readable_text
Brief Report: Clinical Science

Efficacy and safety of efavirenz, raltegravir and dolutegravir in HIV-1/TB co-infection. A multicenter retrospective cohort study in France.

Kherabi, Yousra1,2,3; de Castro, Nathalie1,3; Sellier, Pierre-Olivier3,4; Hamet, Gwenn⁵; Brun, Alexandre⁵; Méchaï, Frédéric⁶; Joly, Véronique²; Yazdanpanah, Yazdan2,3,7; Molina, Jean-Michel1,3,8

¹Department of Infectious diseases, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France

²Department of Infectious diseases, Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Paris, France

³University of Paris, Paris, France

⁴Department of Infectious diseases, Hôpital Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France

⁵COREVIH Ile-de-France Est, Paris, France

⁶Department of Infectious diseases, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, Bobigny, France

⁷INSERM U1137, IAME, Université de Paris, France

⁸INSERM U944, Université de Paris, Paris, France

Correspondence: Yousra Kherabi, Department of Infectious diseases, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France. E-mail: yousra.kherabi@aphp.fr, Telephone: +331 42 49 45 72 - Fax: +331 42 49 90 67

Sources of support: none

The authors report no conflicts of interest related to this work.

JAIDS Journal of Acquired Immune Deficiency Syndromes: May 26, 2022 - Volume - Issue - 10.1097/QAI.0000000000003024

doi: 10.1097/QAI.0000000000003024

Buy

PAP

Abstract

Background:

There are limited data comparing the efficacy and safety of raltegravir and dolutegravir to that of efavirenz in HIV-1/tuberculosis (TB) co-infected patients.

Methods:

We conducted a 10-year retrospective study in four centers in France. We included all HIV-1/tuberculosis co-infected patients starting antiretroviral therapy (ART) with a rifampicin-based regimen, with a plasma HIV RNA level (VL)>1000 copies/mL. The primary endpoint was the proportion of patients with virological success i.e. with VL<50 copies/mL at W48 using an Intention-To-Treat (ITT) analysis, using last-observation-carried-forward to impute missing data. We also assessed ART safety, analyzing treatment discontinuation for adverse events.

Results:

Between 2010 and 2020, 117 patients were included. Thirty-nine (33.3%) were treated with raltegravir and two nucleoside reverse transcriptase inhibitors (NRTIs), 19 (16.2%) with dolutegravir (and two NRTIs) and 59 (50.4%) with efavirenz (and two NRTIs). At W48, the primary endpoint was achieved in 24 patients (61.5%) in the raltegravir group, in 12 (63.2%) in the dolutegravir group, and in 41 (69.5%) in the efavirenz group using an ITT analysis (p=0.68). Emergence of drug resistance in patients with virological failure, defined as a VL>50 copies/mL, was observed in three patients with efavirenz and one patient with raltegravir. Rate of treatment discontinuation for drug-related adverse events was 10.3%, 10.6%, 16.9% for raltegravir, dolutegravir and efavirenz respectively (p=0.67).

Conclusion:

In this retrospective cohort study, raltegravir and dolutegravir yielded similar efficacy and safety results to efavirenz for the treatment of HIV-1/TB co-infected patients.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

# data[].attributes.attachment_link.authors[].name
Individual Subscribers Log in for access

# data[].attributes.attachment_link.title
Efficacy and safety of efavirenz, raltegravir and... : JAIDS Journal of Acquired Immune Deficiency Syndromes

# data[].attributes.attachment_link.description
nfected patients starting antiretroviral therapy (ART) with a rifampicin-based regimen, with a plasma HIV RNA level (VL)>1000 copies/mL. The primary endpoint was the proportion of patients with virological success i.e. with VL<50 copies/mL at W48 using an Intention-To-Treat (ITT) analysis, using las…

# data[].attributes.headline
Caractéristiques des nouveaux patients dépistés VIH pris en charge en 2011 dans une COREVIH. JNI. (2012).

# data[].attributes.subject
Caractéristiques des nouveaux patients dépistés VIH pris en charge en 2011 dans une COREVIH. JNI. (2012).

# data[].attributes.body
Hamet, G., Chansombat, M., Deschaud, M., Tadlaoui-Hbibi, A., Legac, S., Blum, L., Yeni, P.

# data[].attributes.headline
Persistent Low-Level HIV-1 RNA between 20 and 50 copies/mL in Antiretroviral-Treated Patients: Associated Factors and Virological Outcome. AIDS. (2012).

# data[].attributes.subject
Persistent Low-Level HIV-1 RNA between 20 and 50 copies/mL in Antiretroviral-Treated Patients: Associated Factors and Virological Outcome. AIDS. (2012).

# data[].attributes.body
Charpentier, C., Landman, R., Laouénan, C., Joly, V., Hamet, G., Damond, F., Brun-Vézinet, F., Mentré, F., Descamps, D., Yeni, P.

# data[].attributes.headline
Causes of death among HIV-infected patients in a large French hospital network from 2011 to 2015. EACS. (2017).

# data[].attributes.subject
Causes of death among HIV-infected patients in a large French hospital network from 2011 to 2015. EACS. (2017).

# data[].attributes.body
Sellier, P., Abgrall, S. Brun, A., Hamet, G., Ponscarme, D., Alexandre-Castor, G., Parrinello, M., Turpault, I., Garrait, V., Gregoire, V., Bouldouyre, M.A., Delassus, J.L., Bouchaud, O., Bideault, H., Bergmann, J.F., Diamantis, S., Patey, O., Chabrol, A., Son, O., Jeantils, V., Rozenbaum, W., Molina, J.M., for the « Commission Recherche Clinique du COREVIH Ile-de-France Est ».

# data[].attributes.headline
Virological Outcome of Patients Displaying Persistent Low-level Viremia Comprised between 20 and 50 copies/mL. CROI. (2012).

# data[].attributes.subject
Virological Outcome of Patients Displaying Persistent Low-level Viremia Comprised between 20 and 50 copies/mL. CROI. (2012).

# data[].attributes.body
Charpentier, C., Landman, R., Laouénan, C., Joly, V., Hamet, G., Damond, F., Brun-Vézinet, F., Mentré, F., Descamps, D., Yéni, P.

# data[].attributes.headline
Mortality and causes of death in people living with HIV during the COVID-19 pandemic: a multicenter prospective study in the Paris region. EACS. (2021)

# data[].attributes.subject
Mortality and causes of death in people living with HIV during the COVID-19 pandemic: a multicenter prospective study in the Paris region. EACS. (2021)

# data[].attributes.body
Sellier, P., Alexandre-Castor, G., Bouchaud, O., Diamantis, S., Hamet, G., Brun, A., Chabrol, A., Machado,
M., Ponscarme, Bouldouyre, M.-A., Ponscarme, D., De Castro, N., Leroy, P., Turpault, I., Rozenbaum, W.,
Molina, J.-M.

# data[].attributes.headline
Analysis of social and medical characteristics of HIV-infected transgender. EACS. (2011).

# data[].attributes.subject
Analysis of social and medical characteristics of HIV-infected transgender. EACS. (2011).

# data[].attributes.body
Pommier, J.D., Laouénan, C., Lariven, S., Michard, F, Castanedo, G., Hamet, G., Yeni, P.

# data[].attributes.headline
No ealy impact of switching to new single-tablet regimens on low-level residual viremia. HIV Drug Resistance. (2015).

# data[].attributes.subject
No ealy impact of switching to new single-tablet regimens on low-level residual viremia. HIV Drug Resistance. (2015).

# data[].attributes.body
Charpentier, C., Landman, R., Joly, V., Peytavin, G., Michard, F., Hamet, G. Perrier, M., Pichon, M., Yazdanpanah, Y., Descamps, D.

# data[].attributes.headline
Vers une amélioration du recueil des expositions accidentelles à risque viral par les COREVIH ? JNI. (2014).

# data[].attributes.subject
Vers une amélioration du recueil des expositions accidentelles à risque viral par les COREVIH ? JNI. (2014).

# data[].attributes.body
Rouveix, E., Marigot-Outtandy, D., Hamet, G., Gerbe, J., Chansombat, M., Pellissier, G., Elisabeth Bouvet, E.

# data[].attributes.headline
Efficacité et tolérance de la combinaison sofosbuvir/lédipasvir chez les patients VHC du Corevih. Médecine et Maladies Infectieuses. (2017).

# data[].attributes.subject
Efficacité et tolérance de la combinaison sofosbuvir/lédipasvir chez les patients VHC du Corevih. Médecine et Maladies Infectieuses. (2017).

# data[].attributes.body
Gerbe, J., Agher, R., Papot, E., Blanc, C., Brun, A., Hamet, G., Cros, A., Pietri, M.P., Mackoumbou, C., Deschaud, M., Marcou, M., Hamidi, M., Valantin, M.A., Fonquernie, L., Louasse, P., Bouvet, E., Rouveix, E., Rozenbaum, W., Sobel, A., Katlama, C.

# data[].attributes.headline
Synthèse épidémiologique de la file active hospitalière en 2016 en IDF. SFLS. (2017).

# data[].attributes.subject
Synthèse épidémiologique de la file active hospitalière en 2016 en IDF. SFLS. (2017).

# data[].attributes.body
Gerbe, J., Agher, R., Papot, E., Blanc, C., Brun, A., Hamet, G., Cros, A., Pietri, M.P., Mackoumbou, C., Deschaud, M., Marcou, M., Hamidi, M., Valantin, M.A., Fonquernie, L., Louasse, P., Bouvet, E., Rouveix, E., Rozenbaum, W., Sobel, A., Katlama, C.

# data[].attributes.headline
Factors Associated with Low-Level HIV-1 RNA between 20 and 50 copies/ml in Stable Treated Patients. CROI. (2011).

# data[].attributes.subject
Factors Associated with Low-Level HIV-1 RNA between 20 and 50 copies/ml in Stable Treated Patients. CROI. (2011).

# data[].attributes.body
Charpentier, C., Landman, R., Laouénan, C., Joly, Hamet, G., Damond, F., Brun-Vézinet, F., Mentré, F., Descamps, D., Yéni, P.

# data[].attributes.headline
Evaluation des caractéristiques médico-sociales de patients transgenres infectés par le VIH. JNI. (2011).

# data[].attributes.subject
Evaluation des caractéristiques médico-sociales de patients transgenres infectés par le VIH. JNI. (2011).

# data[].attributes.body
Pommier, J.D., Laouénan, C., Lariven, S., Michard, F, Castanedo, G., Hamet, G., Yeni, P.